NCT04675710View on ClinicalTrials.gov

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Thyroid Gland Anaplastic CarcinomaThyroid Gland Squamous Cell Carcinoma
Interventions
PROCEDURE

Conventional Surgery

Undergo surgery

DRUG

Dabrafenib

Given PO

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Trametinib

Given PO

Trial Locations (6)

44195

Cleveland Clinic Taussig Cancer Institute, Cleveland

48109

University of Michigan Rogel Cancer Center, Ann Arbor

55901

Mayo Clinic, Rochester

77030

M D Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute at the University of Utah, Salt Lake City

94304

Stanford School of Medicine, Stanford

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER